Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
1,16-bis(4-methyl-2,5-dioxo-3-furyl)hexadecane
-
tyromycin A
1,2-Acyclic oxytocin
-
slight inhibition of oxytocin degradation, marked inhibition of cystine di-beta-naphthylamide degradation
1-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-1H-indole-6-sulfonamide
2,2'-bipyridine
-
acetic acid-containing chelators potentiate the inhibitory effect of 2,2'-bipyridine. Efficiacy decreases in the order: diethylenetriamine-N,N,N',N'',N''-pentaacetic acid, EDTA, EGTA
2,4,5-trichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzene-1-sulfonamide
-
2,4,5-trichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
2-amino-4-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carbonitrile
-
-
2-amino-4-(3,5-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carbonitrile
-
-
2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carbonitrile
-
-
2-amino-7-hydroxy-4-(3,4,5-trimethoxyphenyl)-4H-chromene-3-carbonitrile
-
-
2-amino-7-hydroxy-4-(3-methoxyphenyl)-4H-chromene-3-carbonitrile
-
-
2-amino-7-hydroxy-4-(4-methoxyphenyl)-4H-chromene-3-carbonitrile
-
-
2-amino-7-hydroxy-4-(pyridin-4-yl)-4H-chromene-3-carbonitrile
-
-
2-methoxyethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
3,4-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzene-1-sulfonamide
-
3,4-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
3,4-dimethyl-N-[3-(1H-tetrazol-5-yl)phenyl]benzene-1-sulfonamide
-
3,4-dimethyl-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
3-([(4-bromo-5-chlorothiophen-2-yl)sulfonyl]amino)-N-methylbenzamide
-
-
3-[(4-bromo-5-chlorothiophene-2-sulfonyl)amino]-N-methylbenzamide
-
4,5-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfinamide
-
4,5-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
4-amino-3-(L-arginylamino)benzoic acid
-
4-amino-3-(L-tyrosylamino)benzoic acid
-
4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoic acid
-
4-bromo-2,6-difluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzene-1-sulfonamide
-
4-bromo-2,6-difluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
4-bromo-2-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzene-1-sulfonamide
-
4-bromo-2-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
4-bromo-5-chloro-N-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
4-bromo-5-chloro-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide
-
-
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
7-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]-1,3-dihydro-2,1,3-benzoxadiazole-4-sulfonamide
-
-
7-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]-2,1,3-benzoxadiazole-4-sulfonamide
-
amino(phenyl)methyl phosphonic acid
-
benzyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
-
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valinate
-
benzyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
-
benzyl N-[3-amino-4-(L-leucylamino)benzoyl]-L-tryptophanate
-
benzyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tryptophanate
-
benzyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-valinate
-
benzyl N-[3-amino-4-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-tryptophanate
-
benzyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
-
benzyl N-[4-amino-3-(D-norleucylamino)benzoyl]-L-valinate
-
benzyl N-[4-amino-3-(L-norleucylamino)benzoyl]-L-tryptophanate
-
benzyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tryptophanate
-
benzyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-valinate
-
benzyl N-[4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
-
butyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
CuCl2
-
0.1 mM, 91% inhibition. 0.01 mM, 87% inhibition
cyclohexylmethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
diethylenetriamine-N,N,N',N'',N''-pentaacetic acid
-
weak
divalinal-angiotensin IV
-
-
ethyl 2,7-diamino-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-(acetylamino)-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-(acetylamino)-7-hydroxy-4-(quinolin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-acetamido-7-hydroxy-4-(3-quinolinyl)-4H-chromene-3-carboxylate
HFI-437
ethyl 2-amino-4-(2,4-dichloropyridin-3-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(2-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(3-chlorophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(3-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(4-chlorophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(4-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(5,8-dihydroquinolin-2-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(pyridin-3-yl)-4H-benzo[g]chromene-3-carboxylate
-
-
ethyl 2-amino-4-(pyridin-3-yl)-4H-benzo[h]chromene-3-carboxylate
-
-
ethyl 2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-6-bromo-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-6-chloro-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-(dimethylamino)-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-(formyloxy)-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-(1,3-thiazol-2-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-(2-nitrophenyl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(4-methylphenyl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(4-nitrophenyl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(pyridin-2-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(pyridin-4-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(quinolin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(quinolin-4-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(thiophen-2-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-[4-(pyridin-2-yl)phenyl]-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-methoxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-8-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
HA-08
a macrocyclic IRAP inhibitor
L-Arg-vasopressin
-
Ki-value for wild-type, mutants G428E, G428D, G428Q above 0.03 mM
L-methionine
-
form I inhibited, form II slightly activated
L-trans-epoxysuccinyl-leucinamido(4-guanidino)-butane
-
E64
L-Val-L-Tyr-L-Ile-2-aminomethylphenylacetic acid
-
inhibits both IRAP and aminopeptidase N and induces proliferation of stem cells at low concentrations
L-Val-L-Tyr-L-Ile-L-Cys-L-Pro-L-Cys
-
cyclic disulfide, angiotensin IV analog, considerably more stable than angiotensin IV toward enzymatic degradation
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-cyclohexylalanine
-
-
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-Phe
Leu-Val-Val-haemorphin 7
-
-
leupeptin
-
0.1 mM, 53% inhibition
LVV hemorphin 7
LVV-H7, IRAP ligands are on the one hand competitive inhibitors of the enzymatic activity of IRAP and on the other hand regulators of its trafficking
methyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
methyl 3-amino-4-(L-arginylamino)benzoate
-
methyl 3-amino-4-(L-norleucylamino)benzoate
-
methyl 3-amino-4-(L-tyrosylamino)benzoate
-
methyl 3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoate
-
methyl 3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoate
-
methyl 4-amino-3-(L-arginylamino)benzoate
-
methyl 4-amino-3-(L-norleucylamino)benzoate
-
methyl 4-amino-3-(L-tyrosylamino)benzoate
-
methyl 4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoate
-
methyl 4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoate
-
methyl 4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoate
-
methyl N-(3,4-diaminobenzoyl)-L-tyrosinate
-
methyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
-
methyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
-
methyl N-[3-amino-4-(L-arginylamino)benzoyl]-L-tyrosinate
-
methyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tyrosinate
-
methyl N-[3-amino-4-(L-tyrosylamino)benzoyl]-L-tyrosinate
-
methyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tyrosinate
-
methyl N-[4-amino-3-(D-norleucylamino)benzoyl]-D-tyrosinate
-
methyl N-[4-amino-3-(L-arginylamino)benzoyl]-D-tyrosinate
-
methyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-threoninate
-
methyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tyrosinate
-
methyl N2-(3,4-diaminobenzoyl)-L-argininate
-
methyl N2-(3,4-diaminobenzoyl)-L-lysinate
-
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-argininate
-
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-(4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-[3-amino-4-(L-arginylamino)benzoyl]-L-lysinate
-
methyl N2-[3-amino-4-(L-leucylamino)benzoyl]-L-lysinate
-
methyl N2-[3-amino-4-(L-norleucylamino)benzoyl]-L-lysinate
-
methyl N2-[3-amino-4-(L-tyrosylamino)benzoyl]-L-lysinate
-
methyl N2-[4-amino-3-(L-norleucylamino)benzoyl]-D-argininate
-
methyl N2-[4-amino-3-(L-norleucylamino)benzoyl]-L-lysinate
-
methyl N2-[4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-lysinate
-
N-(3,4-diaminobenzoyl)-L-tryptophan
-
N-(3-(1H-tetrazol-5-yl)phenyl)-2,3,4-trichlorobenzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-2,5-bis(trifluoromethyl)-benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-2-fluoro-5-(trifluoromethyl)benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-3,4-difluorobenzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-3,5-bis(trifluoromethyl)-benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-3-fluoro-4-(trifluoromethyl)benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-3-methyl-4-(trifluoromethyl)benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-4-methyl-3-(trifluoromethyl)benzenesulfonamide
-
N-(3-amino-4-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
-
N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valine
-
N-(4-amino-3-[[(2R)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
-
N-alpha-tosyl-L-lysylchloromethane
-
-
N-hexanoyl-L-Tyr-L-Ile
a dipeptide derivative from Ang IV, a strong cognitive enhancer and enzyme inhibitor
N-[3-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-sulfonamide
N-[3-(1H-tetrazol-5-yl)phenyl]-2-benzothiophene-1-sulfonamide
-
N-[3-(1H-tetrazol-5-yl)phenyl]-2-benzothiophene-4-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
N-[3-(1H-tetrazol-5-yl)phenyl]biphenyl-4-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]pyridine-3-sulfonamide
N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
N-[3-(1H-tetrazol-5-yl)phenyl][1,1'-biphenyl]-4-sulfonamide
-
N-[3-amino-4-(L-arginylamino)benzoyl]-L-tryptophan
-
N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tryptophan
-
N-[3-amino-4-(L-norleucylamino)benzoyl]-L-valine
-
N-[3-amino-4-(L-tyrosylamino)benzoyl]-L-tryptophan
-
N-[4-amino-3-(D-norleucylamino)benzoyl]-L-valine
-
N-[4-amino-3-(L-arginylamino)benzoyl]-L-tryptophan
-
N-[4-amino-3-(L-arginylamino)benzoyl]-L-valine
-
N-[4-amino-3-(L-norleucylamino)benzoyl]-L-tryptophan
-
N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tryptophan
-
N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-valine
-
N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucine
-
-
N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine
-
-
N2-(2- 8[(1-amino-3-phenylpropyl)(hydroxy)phosphoryl]methyl]-4-methylpentanoyl)-L-lysyl-L-histidyl-L-histidyl-L-alanyl-L-phenylalanyl-L-seryl-L-phenylalanyl-L-lysine
i.e. DG025, an antigenic peptide precursor analogue, enzyme binding structure determination and analysis. The canonical orientation of the two N-terminal residues of DG025 is defined by the transition state nature of the ligand and the hydrophobic and aromatic interactions of the hPhe residue in the S1 specificity pocket of the enzyme (and in particular with Phe544). The remaining of the peptide extends toward the base of the cavity, where it is sandwiched between domains II and IV
N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-ornithine
-
N2-[4-amino-3-(L-leucylamino)benzoyl]-L-lysine
-
N2-[4-amino-3-(L-phenylalanylamino)benzoyl]-L-lysine
-
N2-[4-amino-3-(L-tyrosylamino)benzoyl]-L-lysine
-
p-hydroxymercuribenzoate
-
-
pepstatin A
-
0.1 mM, 70% inhibition
Polyphloretin phosphate
-
-
propyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
puromycin
-
0.1 mM, 36% inhibition. 0.01 mM, 5% inhibition
S-Benzyl-L-cysteinyl-L-prolyl-L-leucyl-glycinamide
-
-
S-benzylcysteine
-
and S-benzylcysteine containing peptides
tert-butyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
tosylphenylalanine-chloromethane
-
-
ZnCl2
-
0.1 mM, 98% inhibition. 0.01 mM, 77% inhibition
[(5R)-6-amino-5-benzyl-2-(2,2-diphenylethyl)-3,6-dioxohexyl][(1R)-1-amino-3-phenylpropyl]phosphinic acid
i.e. DG026, a phosphinic pseudotripeptide that acts as very potent inhibitor of IRAP. DG026 is able to selectively downregulate IRAP-dependent cross-presentation by dendritic cells but leave ERAP1-dependent cross-presentation unaffected. Enzyme binding structure determination and analysis, overview
[2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromen-3-yl](phenyl)methanone
-
50% inhibition at 100 microM
[2-[([[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
[2-[([[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
1,10-phenanthroline
-
competition between 1,10-phenanthroline and the substrate only in presence of EDTA. Inhibitory effect of EDTA plus 1,10-phenanthroline can be completely reversed by Zn2+. Ca2+ and Mg2+ increase the potency of Zn2+ for this process
1,10-phenanthroline
-
IC50: 0.2 mM. Inhibitory effect is substantially potentiated by both EDTA and EGTA. A combined and complete inhibition of the enzyme activity by 0.1 mM EDTA and 0.1 mM 1,10-phenanthroline can be prevented in the presence of 0.04-0.1 mM ZnCl2
1,10-phenanthroline
-
0.1 mM, 83% inhibition. 0.01 mM, 10% inhibition
1-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-1H-indole-6-sulfonamide
-
-
1-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-1H-indole-6-sulfonamide
-
2-mercaptoethanol
-
slight
2-mercaptoethanol
-
inhibition above 1 mM
4,5-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4,5-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
4-bromo-5-chloro-N-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4-bromo-5-chloro-N-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
4-bromo-5-chloro-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4-bromo-5-chloro-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
amastatin
-
CAP II
amastatin
-
0.1 mM, 96% inhibition. 0.01 mM, 79% inhibition
angiotensin 4-8
-
-
angiotensin II
-
-
angiotensin III
-
-
angiotensin IV
-
-
angiotensin IV
-
IC50: 0.00072 mM
angiotensin IV
-
competitive
angiotensin IV
-
angiotensin is the hexapeptide Val-Tyr-Ile-His-Pro-Phe
angiotensin IV
Ang IV, a hexapeptide IRAP inhibitor
angiotensin IV
AngIV, induces an increase in the intracellular calcium concentration in pinealocytes by 72% at 10 nM, but AngIV does not alter cAMP levels
angiotensin IV
IRAP ligands are on the one hand competitive inhibitors of the enzymatic activity of IRAP and on the other hand regulators of its trafficking
bestatin
-
-
bestatin
-
0.1 mM, 43% inhibition. 0.01 mM, 12% inhibition
Cd2+
-
-
Co2+
-
reverses EDTA inhibition
Co2+
-
at high concentration inhibition
Co2+
-
reverses EDTA inhibition
Co2+
-
at high concentration inhibition
Co2+
-
at high concentration inhibition
cysteine
-
-
divalinal
-
-
EDTA
-
weak
EDTA
-
form I inhibited, form II uninfluenced or slightly activated
EGTA
-
weak
Hg2+
-
-
iodoacetic acid
-
slightly
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-Phe
-
i.e.angiotensin IV
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-Phe
-
i.e. angiotensin IV, adopts a gamma-turn in the C-terminal of its bioactive conformation
LVV-H7
-
-
LVV-hemorphin 7
-
-
Mn2+
-
at high concentration inhibition
Mn2+
-
at high concentration inhibition; reverses EDTA inhibition
N-[3-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-sulfonamide
-
N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
N-[3-(1H-tetrazol-5-yl)phenyl]pyridine-3-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]pyridine-3-sulfonamide
-
N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
Ni2+
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
Pb2+
-
inhibits at pH 6.0, not at pH 7.4
prostaglandin E-1
-
at pH 6.2, not at pH 6.8 and 7. 4
prostaglandin E-1
-
pH-dependent inhibition
prostaglandin E2
-
at pH 6.2, not at pH 6.8 and 7. 4
prostaglandin E2
-
pH-dependent inhibition
prostaglandin F-2alpha
-
at pH 6.2, not at pH 6.8 and 7. 4
prostaglandin F-2alpha
-
pH-dependent inhibition
prostaglandin F-2alpha
-
-
Zn2+
-
-
Zn2+
-
inhibition at pH 6.0 not at pH 7.5
Zn2+
-
at high concentration
additional information
-
inhibitory potency in decreasing order: angiotensin III, angiotensin IV, LVV-hemorphin 7, divalinal/angiotensin IV, angiotensin II, angiotensin 4-8
-
additional information
-
inhibitory potency in decreasing order: angiotensin IV, angiotensin III, LVV-hemorphin 7, divalinal/angiotensin IV, angiotensin 4-8, angiotensin III
-
additional information
-
EDTA has no effect
-
additional information
-
inhibitory potency in decreasing order: angiotensin IV, angiotensin III, divalinal/angiotensin IV, LVV-hemorphin 7, angiotensin 4-8, angiotensin III
-
additional information
inhibition of insulin-regulated aminopeptidase (IRAP) by aryl sulfonamides, structural basis, docking and moelling, molecular dynamics simulations, overview. The fluorinated series exhibit high metabolic stability in microsomes and encompasses compounds with submicromolar affinity. The binding modes are thoroughly examined by molecular dynamics (MD)-related methods for binding affinity estimation for the whole series of aryl sulfonamides
-
additional information
-
inhibition of insulin-regulated aminopeptidase (IRAP) by aryl sulfonamides, structural basis, docking and moelling, molecular dynamics simulations, overview. The fluorinated series exhibit high metabolic stability in microsomes and encompasses compounds with submicromolar affinity. The binding modes are thoroughly examined by molecular dynamics (MD)-related methods for binding affinity estimation for the whole series of aryl sulfonamides
-
additional information
virtual screening from three-dimensional structure models for transition state analogue inhibitors of IRAP based on quantum mechanically derived reaction coordinates, overview. Transition state and high energy intermediate mimetics have the potential to be very potent enzyme inhibitors. Method development and evaluation
-
additional information
enzyme IRAP undergoes a conformational change upon inhibitor binding, docking study. Analysis of structural determinants for inhibitor selectivity, overview. Significant affinity is generated by structural elements common to all homologous enzymes: the active-site Zn(II) atom, the catalytic Tyr549 and Glu465, N-terminus recognition by Glu295, Glu431, and Glu487, and the S1 specificity residue Phe544
-
additional information
-
inhibitory potency in decreasing order: angiotensin IV, angiotensin III, divalinal/angiotensin IV, LVV-hemorphin 7, angiotensin 4-8, angiotensin III
-